This is a routine early-stage clinical update with no data readout until H2 2027. No immediate catalyst for the stock. Monitor for DSMB safety reviews and any interim updates, but the next material event is topline data release.
Price Chart
Executive Summary
Vaxcyte dosed the first participant in a Phase 1 first-in-human study of VAX-A1, a prophylactic vaccine candidate for Group A Streptococcus. This is an early-stage clinical milestone with no efficacy data yet; topline results are not expected until H2 2027.
Key Facts
- First participant dosed in Phase 1 study of VAX-A1 for Group A Strep.
- Study is randomized, double-blind, placebo-controlled, dose-escalation, two-stage, enrolling ~80 healthy adults aged 18-40.
- Primary objective: safety and tolerability; secondary: antigen-specific immune responses.
- Topline data expected in second half of 2027.
- Group A Strep causes ~800M new cases and >600,000 deaths annually worldwide; no approved vaccine exists.
- VAX-A1 targets four conserved antigens (ScpA, SLO, SpyAD, modified GACPR) using Vaxcyte's cell-free protein synthesis platform.
Financial Impact
No financial data disclosed; early-stage clinical milestone with no revenue impact.
Risk Factors
- Clinical failure or safety issues in Phase 1 could halt the program.
- Long timeline to data (H2 2027) means no near-term catalyst.
- Group A Strep vaccine development has historically been challenging with prior failures.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305592 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | Insider Cluster | $55.92 $61.58 | ▲ +10.12% | ▲ +10.72% | $56.69 (+1.38%) |
Jul 6, 2026 12w ago | Insider Cluster | $60.67 $53.53 | ▼ −11.77% | ▼ −13.10% | $56.69 (−6.56%) |
Jul 6, 2026 12w ago | Insider Cluster | $60.67 $53.53 | ▼ −11.77% | ▼ −13.10% | $56.69 (−6.56%) |
Jun 26, 2026 13w ago | 144 | $57.72 $54.66 | ▼ −5.30% | ▼ −5.02% | $56.69 (−1.78%) |
Jun 23, 2026 14w ago | 8-K | $53.87 $56.00 | ▲ +3.95% | ▲ +2.02% | $56.69 (+5.23%) |
Jun 19, 2026 15w ago | Insider Cluster | $52.11 $56.20 | ▲ +7.85% | ▲ +8.00% | $56.69 (+8.79%) |
Jun 2, 2026 17w ago | Press Release | $46.93 $58.39 | ▲ +24.42% | ▲ +25.42% | $56.69 (+20.80%) |
May 6, 2026 21w ago | 8-K | $51.48 $46.93 | ▲ +8.84% | ▲ +11.97% | $56.69 (−10.12%) |
Apr 23, 2026 23w ago | DEFA14A | $59.49 $47.39 | ▼ −20.34% | ▼ −24.37% | $56.69 (−4.71%) |
Apr 1, 2026 26w ago | Insider Cluster | $58.50 $57.32 | ▼ −2.02% | ▼ −11.74% | $56.69 (−3.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access